Skip to main content
Have a personal or library account? Click to login
Treatment of Osteoporosis Cover

Treatment of Osteoporosis

Archives of Industrial Hygiene and Toxicology
Volume 58 (2007): Issue 1 (March 2007)
By: ,  ,  ,   and    
Open Access
|Mar 2007
References

References

  1. Simonelli C, Weiss TW, Morancey J, Swanson L, Chen YT. Prevalence of vitamin D inadequacy in a minimal trauma fracture population.2005;21:1069-74.
    Open DOISearch in Google Scholar
  2. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen lossmediation by interleukin-6.1992;257:88-91.
    Open DOISearch in Google Scholar
  3. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.1997;99:1699-703.
    Open DOISearch in Google Scholar
  4. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells.1991;88:6613-7.
    Open DOISearch in Google Scholar
  5. Pennisi E. Drugs' link to genes reveals estrogen's many sides.1996;273:1171.
    Open DOISearch in Google Scholar
  6. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.1994;8:21-30.
    Search in Google Scholar
  7. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease.2003;349: 523-34.
    Open DOISearch in Google Scholar
  8. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid.2006;21:765-71.
    Open DOISearch in Google Scholar
  9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.1998;280:605-13.
    Open DOISearch in Google Scholar
  10. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review.2002;288:872-81.
    Open DOISearch in Google Scholar
  11. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life.2003;348:1839-54.
    Open DOISearch in Google Scholar
  12. Black LJ, Sato M, Rowley ER. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.1994;93:63-9.
    Open DOISearch in Google Scholar
  13. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.1997;337:1641-7.
    Open DOISearch in Google Scholar
  14. Sambrook P. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?2005;19:975-81.
    Open DOISearch in Google Scholar
  15. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol raloxifene.1996;273:1222-5.
    Open DOISearch in Google Scholar
  16. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.1995;270:1354-7.
    Open DOISearch in Google Scholar
  17. Barrett-Connor E, Mosca L, Collins P i sur. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.2006;355:125-37.
    Open DOISearch in Google Scholar
  18. Bevers TB. Raloxifene and the prevention of breast cancer.2006;7:2301-7.
    Open DOISearch in Google Scholar
  19. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud Ke, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial.1999;281:2189-97.
    Open DOISearch in Google Scholar
  20. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. (CORE Investigators): Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.2004;96:1751-61.
    Open DOISearch in Google Scholar
  21. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.1990;322:1265-71.
    Open DOISearch in Google Scholar
  22. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.1999;56:131-40.
    Open DOISearch in Google Scholar
  23. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vananen HK, Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.2002;61:1255-62.
    Search in Google Scholar
  24. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.2000;373:231-41.
    Open DOISearch in Google Scholar
  25. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras.1998;13:581-9.
    Open DOISearch in Google Scholar
  26. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.1999;255:491-4.
    Open DOISearch in Google Scholar
  27. Rodan GA, Reszka AA. Bisphosphonate mechanism of action.2002;2:571-7.
    Open DOISearch in Google Scholar
  28. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses.1999;9(Suppl 2):S66-80.
    Open DOISearch in Google Scholar
  29. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.2006;22:919-28.
    Open DOISearch in Google Scholar
  30. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.2005;80:856-61.
    Open DOISearch in Google Scholar
  31. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women.2004;350:1189-99.
    Open DOISearch in Google Scholar
  32. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group.1998;338:485-92.
    Open DOISearch in Google Scholar
  33. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.2004;255:503-11.
    Open DOISearch in Google Scholar
  34. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.2006;16:753-61.
    Open DOISearch in Google Scholar
  35. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.2006;355:675-84.
    Open DOISearch in Google Scholar
  36. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebocontrolled trial.2000;85:1895-900.
    Search in Google Scholar
  37. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.2002;71:103-11.
    Open DOISearch in Google Scholar
  38. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.1999;282:1344-52.
    Open DOISearch in Google Scholar
  39. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.2000;11:83-91.
    Open DOISearch in Google Scholar
  40. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study.1996;19:527-33.
    Open DOISearch in Google Scholar
  41. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.2001;16:1871-8.
    Open DOISearch in Google Scholar
  42. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.1997;103:298-307.
    Open DOISearch in Google Scholar
  43. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.2005;20:1315-22.
    Open DOISearch in Google Scholar
  44. Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003;32:273-84.
    Open DOISearch in Google Scholar
  45. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin.1983;57:819-24.
    Open DOISearch in Google Scholar
  46. Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain.2003;9:2659-76.
    Open DOISearch in Google Scholar
  47. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.2007;26:44-9.
    Open DOISearch in Google Scholar
  48. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.2000;109:267-76.
    Search in Google Scholar
  49. Lyritis GP, Trovas G. Analgesic effects of calcitonin.2002;30:71-4.
    Open DOISearch in Google Scholar
  50. Miyauchi A, Notoya K, Taketomi S. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function.1996;137:3544-50.
    Open DOISearch in Google Scholar
  51. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.2001;285:1482-8.
    Open DOISearch in Google Scholar
  52. Darby AJ, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis.1981;33:199-204.
    Open DOISearch in Google Scholar
  53. Parsons JA, Potts JT Jr. Physiology and chemistry of parathyroid hormone.1972;1:33-78.
    Open DOISearch in Google Scholar
  54. Canalis E, Centrella M, Burch W, McCarthy TL. Insulinlike growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures.1989;8:60-5.
    Open DOISearch in Google Scholar
  55. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.2001;344:1434-41.
    Open DOISearch in Google Scholar
  56. Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits.1999;14:536-45.
    Open DOISearch in Google Scholar
  57. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.2001;16:1846-53.
    Open DOISearch in Google Scholar
  58. Lau KH, Farley JR, Freeman TK, Baylink DJ. A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase.1989;38:858-68.
    Open DOISearch in Google Scholar
  59. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.2003;349:1216-26.
    Open DOISearch in Google Scholar
  60. Ettinger B, San Martin JA, Crans GG, Pavo I 2004 Differential effects of teriparatide after treatment with raloxifene or alendronate.19:745-51.
    Open DOISearch in Google Scholar
  61. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.1998;13:1051-5.
    Open DOISearch in Google Scholar
  62. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.2003;349:1207-15.
    Open DOISearch in Google Scholar
  63. Whitfield JF. The bone growth-stimulating PTH and osteosarcoma.2001;6:7.
    Search in Google Scholar
  64. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells.1983;222:330-2.
    Open DOISearch in Google Scholar
  65. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.1990;322:802-9.
    Open DOISearch in Google Scholar
  66. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis.1991;1:155-61.
    Open DOISearch in Google Scholar
  67. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.2004;350:459-68.
    Open DOISearch in Google Scholar
  68. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration.1996;11:1302-11.
    Open DOISearch in Google Scholar
  69. Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone.2001;69:121-29.
    Open DOISearch in Google Scholar
  70. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice.2002;51:906-11.
    Open DOISearch in Google Scholar
  71. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y. An uncoupling agent containin strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.1993;9:607-15.
    Search in Google Scholar
  72. Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.2003;14(Suppl 3):S19-24.
    Open DOISearch in Google Scholar
  73. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study.2005;90:2816-22.
    Open DOISearch in Google Scholar
  74. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial.2002;87:206-6.
    Search in Google Scholar
  75. Quarles LD. Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling?1997;12:1971-4.
    Open DOISearch in Google Scholar
  76. Baron R. Biology of the osteoclast. U: Mundy GR, Martin TJ, urednici. Physiology and Pharmacology of Bone. Handbook of Experimental Pharmacology; Berlin: Springer-Verlag; 1993. str. 111-47.
    Open DOISearch in Google Scholar
  77. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene.1990;345:442-4.
    Open DOISearch in Google Scholar
  78. Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H. Impairment of macrophage colonystimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse.1990;5:781-9.
    Open DOISearch in Google Scholar
  79. Kodama H, Yamasaki A, Nose M, Niida S, Ohgame Y, Abe M, Kumegawa M, Suda T. Congenital osteoclast deficiency in osteopetrotic op/op mice is cured by injections of macrophage colony stimulating factor.1991;173:269-72.
    Open DOISearch in Google Scholar
  80. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.1991;64:693-702.
    Open DOISearch in Google Scholar
  81. Yoneda T, Lowe C, Lee CH, Gutierrez G, Niewolna M, Williams PJ, Izbicka E, Uehara Y, Mundy GR. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorptionand hypercalcemia1993;91:2791-5.
    Open DOISearch in Google Scholar
  82. Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M. Inhibition of osteoclastic bone resorptionby echistatin an "arginylglycyl-aspartyl" (RDG) containing peptide.1993;132:1411-3.
    Open DOISearch in Google Scholar
  83. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL. A peptidomimetic antagonist of the αβintegrin inhibits bone resorptionand prevents osteoporosis1997;99:2284-92.
    Open DOISearch in Google Scholar
  84. Horton MA, Davies J. Perspectives-adhesion receptors in bone. J.1989;4:803-8.
    Open DOISearch in Google Scholar
  85. Vaes E. The action of parathyroid hormone on the excretion and synthesis of lysosomal enzymes and on the extracellular release of acid by bone cells.1968;39:676-97.
    Open DOISearch in Google Scholar
  86. Eilon G, Raisz LG. Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture.1978;103:1969-75.
    Open DOISearch in Google Scholar
  87. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA. Proteolytic activity of human osteoclast cathepsin K-expression, purification, activation, and substrate identification.1996;271:12517-24.
    Open DOISearch in Google Scholar
  88. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts.1996;271:12511-6.
    Open DOISearch in Google Scholar
  89. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.2000;192:463-74.
    Open DOISearch in Google Scholar
  90. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of soluble RANK-IgG Fc (RANK.Fc) fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.2001;61:2572-8.
    Search in Google Scholar
  91. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice.1992;90:1622-7.
    Open DOISearch in Google Scholar
  92. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts.1993;90:4485-9.
    Open DOISearch in Google Scholar
  93. Abu-Amer Y, Tondravi MM. NFkappaB and bone: the breaking point.1997;3:1189-90.
    Open DOISearch in Google Scholar
  94. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formationand.2003;111:1771-82.
    Open DOISearch in Google Scholar
  95. Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women.1993;77:683-6.
    Search in Google Scholar
  96. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
    Open DOISearch in Google Scholar
  97. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass indeks on bone mineral density in men and women: the Framingham Study.1993;8:567-73.
    Open DOISearch in Google Scholar
  98. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption.2005;11:76-81.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10004-007-0009-3 | Journal eISSN: 1848-6312 (formerly 0004-1254) | Journal ISSN: 0004-1254
Journal RSS Feed
Language: English
Page range: 55 - 71
Published on: Mar 28, 2007
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Keywords:
bisphoshonates,
estrogens,
parathyroid hormone,
selective estrogen receptor modulators,
strontium ranelate
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2007 Petra Šimić, Zlatko Giljević, Velimir Šimunić, Slobodan Vukičević, Mirko Koršić, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons License.

Volume 58 (2007): Issue 1 (March 2007)
Previous article